Henrique D. Teixeira

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

Emma Guttman‐Yassky, Henrique D. Teixeira, Eric L. Simpson et al. · The Lancet · 2021 · 543 citations

Life Sciences, Dermatology, Pharmacotherapy +13

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

Andrew Blauvelt, Henrique D. Teixeira, Eric L. Simpson et al. · JAMA Dermatology · 2021 · 485 citations · Full text

Medicine, Dermatology, Pharmacotherapy +14

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

Kristian Reich, Henrique D. Teixeira, Marjolein de Bruin‐Weller et al. · The Lancet · 2021 · 389 citations

Medicine, Dermatology, Pediatrics +16

Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

Emma Guttman‐Yassky, Diamant Thaçi, Aileen L. Pangan et al. · Journal of Allergy and Clinical Immunology · 2019 · 357 citations · Full text

Medicine, Dermatology, Pharmacology +13

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study

Alexa B. Kimball, Jeffrey M. Sobell, Christos C. Zouboulis et al. · Journal of the European Academy of Dermatology and Venereology · 2015 · 193 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13